tc99m-tilmanocept
Trade name: Lymphoseek
Recombinant proteinapprovedImaging agent
Approved
Mar 13, 2013
Technetium (99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent approved for the imaging of lymph nodes. It is used to locate those lymph nodes which may be draining from tumors, and assist doctors in locating those lymph nodes for removal during surgery. — NCATS
Clinical trial activity
29 trials · 16 clinical orgs · 2 marketing orgs
Phase 1
9
Phase 2
15
Phase 3
4
Phase 4
5
Earliest trial started Apr 1, 2008 (NCT00671918)
Timeline
2000s
- Jan 1, 2008
Navidea Biopharmaceuticals — Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
- Mar 13, 2013
Navidea Biopharmaceuticals — Earliest FDA Approval
- Mar 13, 2013
Cardinal Health — NDA Secondary Org
- Mar 13, 2013
Navidea Biopharmaceuticals — NDA Organization
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Anus Neoplasms · Phase 2
- Arthritis, Rheumatoid · Phase 3
- Breast Neoplasms · Phase 4
- Central Nervous System Neoplasms · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 4
- Heart Diseases · Phase 2
- HIV Infections · Early Phase 1
- Melanoma · Phase 4
- Neoplasm Metastasis · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 1
- Rectal Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma, Kaposi · Phase 2
- Sentinel Lymph Node · Phase 4
- Sentinel Lymph Node Biopsy · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Macrophage mannose receptor 1INHIBITOR
MRC1 inhibitor
- Unspecified targetOTHER
Diagnostic agent
- Unspecified targetOTHER
Diagnostic
Approval history
- approvedMar 13, 2013
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
- Imaging
- 99-technetium
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaTechnetium (99mTc) tilmanocept ↗
- NCATS8IHI69PQTC ↗
- ChEMBLCHEMBL5315077 ↗
- ChEMBLCHEMBL2108726 ↗
Also known as
- 1600
- 99mtc-dtpa-mannosyl-dextran
- (99m)tc-tilmanocept
- 99mtc-tilmanocept
- lymphoseek
- lymphoseek
- lymphoseek
- lymphoseek
- tc 99m tilmanocept
- tc99m tilmanocept
- tc99m-tilmanocept
- tc-dtpa-mannosyl-dextran
- technetium (99mtc) tilmanocept
- technetium (99mtc) tilmanocept
- technetium (99mtc) tilmanocept
- technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
- technetium tc 99m tilmanocept
- technetium tc 99m tilmanocept
- technetium tc 99m tilmanocept
- technetium tc-99m tilmanocept
- technetium tc-99m tilmanocept
- technetium tc-99m tilmanocept
- technetium tc-99m tilmanocept
- technetium tc-99m tilmanocept
- tilmanocept
- tilmanocept
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07159074 | Phase 2 | Sep 17, 2025 | Duke University, Foundation for Sarcoidosis Research |
| NCT05246280 | Phase 3 | Mar 2, 2022 | Navidea Biopharmaceuticals |
| NCT04947137 | Phase 2 | May 12, 2021 | Navidea Biopharmaceuticals |
| NCT04663126 | Early Phase 1 (Phase 1) | Jan 31, 2021 | University of Lausanne |
| NCT04487912 | Phase 4 | Nov 24, 2020 | Ghent University, Norgine |
| NCT04511026 | Phase 2 | Sep 30, 2020 | Stanford University |
| NCT04261179 | Phase 4 | Mar 31, 2020 | University of Barcelona |
| NCT04078191 | Phase 2 | Dec 31, 2019 | Navidea Biopharmaceuticals |
| NCT04096716 | Phase 1 | Sep 30, 2019 | Washington University in St. Louis |
| NCT03938636 | Phase 2 | Apr 8, 2019 | Navidea Biopharmaceuticals |
| NCT03405142 | Phase 2 | Jul 16, 2018 | National Cancer Institute (NCI), Stanford University |
| NCT03332940 | Phase 1 | Dec 6, 2017 | Navidea Biopharmaceuticals |
| NCT03241446 | Phase 1 | Sep 30, 2017 | Navidea Biopharmaceuticals |
| NCT03157167 | Early Phase 1 (Phase 1) | Jul 15, 2017 | National Cancer Institute (NCI), National Institutes of Health (NIH), Navidea Biopharmaceuticals |
| NCT03199560 | Phase 4 | Jun 22, 2017 | Memorial Health University Medical Center |
| NCT03029988 | Phase 1 | May 1, 2017 | National Cancer Institute (NCI), National Institutes of Health (NIH), Navidea Biopharmaceuticals |
| NCT02865434 | Phase 1 | Jan 1, 2017 | Navidea Biopharmaceuticals |
| NCT02857608 | Phase 2 | Sep 1, 2016 | Cardinal Health |
| NCT02683421 | Phase 1 | Jul 1, 2016 | Navidea Biopharmaceuticals |
| NCT02509585 | Phase 2 | Jan 1, 2016 | Cardinal Health |
Showing 20 of 29 trials
Page 1 / 2
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Navidea Biopharmaceuticals | For profit | 15 | 14 | 4 | 2008 |
| Cardinal Health | Academic/Hospital | 4 | 3 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2017 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2017 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| University of California, San Diego | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Foundation for Sarcoidosis Research | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Ghent University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Kettering Health Network | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Maimonides Medical Center | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Memorial Health University Medical Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Norgine | For profit | 1 | 0 | 1 | 2020 |
| University of Barcelona | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Lausanne | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2019 |
16 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Cardinal Health | Academic/Hospital | NDA2 | Mar 13, 2013 |
| Navidea Biopharmaceuticals | For profit | NDA | Mar 13, 2013 |